Prenatal Chromosomal Screening: NIPT, Serum Screening, CVS & Amniocentesis
Chromosomal screening assesses risk of aneuploidy (trisomy 21/18/13, sex chromosome differences). Options range from non-invasive screening to diagnostic testing.
Screening Tests (Risk Assessment, Not Diagnostic)
| Test | Timing | Components | Detection (T21) | False Positive |
| NIPT (cfDNA) | ≥10 wks | Maternal blood → fetal placental DNA | >99% | <0.1% |
| First Trimester Combined | 11–13+6 wks | PAPP-A, β-hCG + NT ultrasound | 85–90% | 5% |
| Second Trimester Quad | 15–22 wks | AFP, hCG, estriol, inhibin-A | 81% | 5–7% |
| Integrated/Sequential | Combined 1st + 2nd | Both serum + NT | 90–95% | 2–5% |
Diagnostic Tests (Definitive Karyotype)
- CVS (10–13 wks): Transcervical/transabdominal chorionic villi sampling. Miscarriage risk ~0.2–0.5%. Detects all chromosomal anomalies; cannot detect neural tube defects (AFP needed).
- Amniocentesis (≥15 wks): Amniotic fluid culture. Miscarriage risk ~0.1–0.3%. Detects chromosomal + NTDs (AFP).
Decision Framework
- Counseling: values, risk tolerance, desire for diagnostic certainty.
- Screening first (NIPT preferred for performance).
- If screen positive → diagnostic confirmation (CVS/amnio) before irrevocable decisions.
- If screen negative → reassurance; diagnostic still optional.
Emerging
- Genome-wide NIPT (microdeletions, CNVs) — higher false positive, counseling complexity.
- Non-invasive fetal karyotyping (whole genome) — research phase.
All testing is voluntary. Shared decision-making essential.
Pregnancy & Health - Related Articles